ReproCELLReproCELL Incorporated4978東証グロース化学FY ending Mar 2026, consolidated, J-GAAP
It lost about ¥39 for every ¥100 of sales at the operating level. Revenue changed -25.0% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | — | —× | -7.1% | —× | — |
| 2023 | — | —× | -3.7% | —× | — |
| 2024 | — | —× | -0.4% | —× | — |
| 2025 | 3.5% | 0.32× | 1.1% | 1.09× | 1.2% |
| 2026 | — | —× | -6.1% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 2,235 | 2,953 | 2,427 | 2,979 | 2,234 |
| Cost of revenue | 1,431 | 1,812 | 1,306 | 1,330 | 1,218 |
| Gross profit | 803 | 1,141 | 1,121 | 1,649 | 1,015 |
| SG&A | 1,451 | 1,497 | 1,530 | 1,779 | 1,875 |
| Operating income | -647 | -356 | -409 | -130 | -860 |
| Pretax income | -574 | -304 | -29 | 45 | -587 |
| Income tax | 1 | 2 | 3 | -58 | 4 |
| Net income attributable to owners | -575 | -305 | -31 | 103 | -592 |
| Operating margin | -29.0% | -12.1% | -16.9% | -4.4% | -38.5% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥2.64B | ¥1.91B | ¥2.94B | ¥2.82B | ¥2.6B |
| Total assets | ¥8.1B | ¥8.36B | ¥9.05B | ¥9.67B | ¥9.65B |
| Net assets | ¥7.25B | ¥7.58B | ¥8.31B | ¥8.98B | ¥8.85B |
| Share capital | ¥1.72B | ¥2.02B | ¥2.32B | ¥2.69B | ¥2.72B |
| Property, plant and equipment | ¥97.8M | ¥101.2M | ¥199.6M | ¥241.7M | ¥282.4M |
| Intangible assets excluding goodwill | ¥29.1M | ¥15M | ¥24.2M | ¥26.8M | ¥13.8M |
| Goodwill | ¥16.3M | ¥13.6M | ¥10.9M | ¥8.1M | ¥5.4M |
| Investment securities | ¥2.54B | ¥1.01B | ¥1.38B | ¥4.4B | ¥1.91B |
| Current assets | ¥5.38B | ¥7.18B | ¥7.4B | ¥4.9B | ¥7.33B |
| Current liabilities | ¥827.3M | ¥749.7M | ¥678.4M | ¥640.6M | ¥617.2M |
| Total liabilities | ¥844.5M | ¥780.6M | ¥741M | ¥685.8M | ¥805.6M |
| Equity attributable to owners of parent | ¥7.28B | ¥7.59B | ¥8.15B | ¥8.99B | ¥8.46B |
| Retained earnings | -¥750.4M | -¥515.5M | -¥546.9M | ¥58.3M | -¥533.4M |
| Treasury stock | -¥916K | -¥916K | -¥916K | -¥916K | -¥916K |
EDINET (FSA Japan)
有価証券報告書－第24期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第23期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第22期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第21期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第20期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第19期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 42 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.